Multibiomarker analysis in patients with acute myocardial infarction.

ABSTRACT

BACKGROUND: Novel biomarkers representing different pathobiological pathways and their role in patients with acute myocardial infarction (AMI) were studied. METHODS: We retrospectively analysed serum levels of soluble suppression of tumorigenicity (sST2), growth-differentiation factor-15 (GDF-15), soluble urokinase plasminogen activator receptor (suPAR), heart-type fatty acid-binding protein (H-FABP) and plasma fetuin A in blood of patients with AMI (STEMI, n = 61; NSTEMI, n = 57) compared to controls with excluded coronary artery disease (n = 76). Furthermore, detailed correlation analysis was performed. RESULTS: Compared with controls, in patients with STEMI and NSTEMI higher levels expressed as median of sST2 in pg/mL (STEMI 13210·9, NSTEMI 11989·1, control 5248; P < 0·001), GDF-15 in pg/mL (STEMI 818·8, NSTEMI 677·5, control 548·6; P < 0·001), suPAR in pg/mL (STEMI 3461·1, NSTEMI 3466·7, control 2463·6; P < 0·001), H-FABP in ng/mL (STEMI 5·8, NSTEMI 5·4, control 0·0; P < 0·001) and lower plasma fetuin A levels in µg/mL (STEMI 95, NSTEMI 54, control 116·6; P < 0·001) were detected. Correlation analysis found clinical and biochemical parameters such as ejection fraction, length of hospital stay, creatine kinase, NT-proBNP and hs Troponin T levels as well as inflammatory markers (CRP, leucocytes) to be significantly correlated with novel biomarkers. CONCLUSION: Plasma levels of novel biomarkers were significantly elevated (sST2, GDF-15, H-FABP, suPAR) or inversely downregulated (fetuin A) in patients with AMI compared to a control group with excluded coronary artery disease. Significant correlations with various clinical parameters and standard biochemical markers were found.